Giovanni Caforio, Bristol Myers Squibb CEO (Pablo Martinez Monsivais/AP Images)

Star­ing at a down quar­ter for Op­di­vo, Bris­tol My­ers keeps its eyes on price com­pe­ti­tion po­ten­tial in packed PD-1 mar­ket

De­spite its stand­ing as one of the best­selling an­ti-PD-1s, Bris­tol My­ers Squibb can ill af­ford a down quar­ter for its lead­ing I/O amid a packed — and grow­ing — class. With Covid-19 al­ready nip­ping at sales, the drug­mak­er is al­so keep­ing close watch for a po­ten­tial dis­count­ed dis­rupter in the PD-1 class, which could come soon­er rather than lat­er.

Bris­tol My­ers’ an­ti-PD-1 Op­di­vo post­ed dis­ap­point­ing sales for Op­di­vo in the first quar­ter, down 3% from the same time pe­ri­od last year at $1.72 bil­lion, ac­cord­ing to earn­ings re­leased Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.